<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9845">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689008</url>
  </required_header>
  <id_info>
    <org_study_id>DFSC-2023(CR)-01</org_study_id>
    <nct_id>NCT05689008</nct_id>
  </id_info>
  <brief_title>UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia</brief_title>
  <official_title>Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe and Critical COVID-19 With Refractory Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized, controlled, open-labeled interventional clinical trial is to&#xD;
      test the efficacy and safety of umbilical cord mesenchymal stem cells (UC- MSCs) in the&#xD;
      treatment of severe and critical COVID-19 patients with refractory hypoxia even after&#xD;
      sufficient standard treatment according to the tenth edition of Chinese guidelines for&#xD;
      COVID-19 infection. The main questions it aims to answer are: 1. The efficacy of UC-MSCs in&#xD;
      the treatment of severe and critical COVID-19 patients with refractory hypoxia. 2. The safety&#xD;
      of UC-MSCs in the treatment of severe and critical COVID-19 patients. 3. The potential immune&#xD;
      mechanisms of UC- MSCs in the treatment of severe and critical COVID-19 patients.&#xD;
      Participants will receive standard therapy, or the UC-MSCs treatment. For the standard&#xD;
      treatment, it will be conducted according the 10th edition of Chinese guidelines for severe&#xD;
      or critical COVID-19 infection. For UC-MSCs treatment, participants will be given UC-MSCs&#xD;
      instillation at the first and fourth day after assignment. Blood examples will be taken at&#xD;
      indicated time for arterial blood gas analysis and other tests. And participants should also&#xD;
      objectively report their symptoms change and other information related to the treatment as&#xD;
      listed the research protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2023</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation index</measure>
    <time_frame>Change from baseline Oxygenation index (PaO2/FiO2) at 1,3,7,14,28 (or before the day of discharge if participants discharge within 28 days) days after the treatment.</time_frame>
    <description>Oxygenation index is the artery partial pressure of oxygen divided by the concentration of inhaled oxygen.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mesenchymal Stem Cell</condition>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC-MSCs treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment on the basis of standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UC-MSCs treatment</intervention_name>
    <description>Participants will receive two doses of UC-MSCs treatment, each dose will contain 1*10^6 cells/kg suspended in 100 ml albumin solution.</description>
    <arm_group_label>UC-MSCs treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The age ranges from 18 to85 (inclusive), regardless of gender.&#xD;
&#xD;
          -  Patients who still have refractory hypoxia after sufficient standard treatment for&#xD;
             severe and critical COVID-19 pneumonia following the suggestion of the Chinese&#xD;
             diagnostic criteria for COVID-19 pneumonia in the Diagnosis and Treatment Plan for&#xD;
             COVID-19 Pneumonia (Tentative tenth Edition).&#xD;
&#xD;
          -  20kg/m2≤body mass index(BMI)≤30 kg/m2.&#xD;
&#xD;
          -  Volunteer to participate in this clinical study and sign the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after&#xD;
             organ transplantation.&#xD;
&#xD;
          -  T lymphocyte abnormality (allogeneic may be considered, depending on clinical&#xD;
             opinion), HIV positive.&#xD;
&#xD;
          -  Highly allergic or have a history of severe allergy, especially Interleukin-2 allergy.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Patients with severe autoimmune disease history; Allergies to all biological reagents&#xD;
             in this treatment, such as Interleukin-2.&#xD;
&#xD;
          -  Patients with serious complications, including chronic cardiac insufficiency (NYHA&#xD;
             cardiac function grading assessment of cardiac function grade III - IV), chronic renal&#xD;
             insufficiency (CKD stage 3 and above); Chronic liver insufficiency (Child-Pugh&#xD;
             score&gt;7); Patients with malignant tumors.&#xD;
&#xD;
          -  Patients with pulmonary embolism or acute coronary syndrome.&#xD;
&#xD;
          -  Patients with severe organ dysfunction caused by other diseases.&#xD;
&#xD;
          -  There are other situations that the researcher thinks are not suitable to participate&#xD;
             in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongmin Liu, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Li, Dr.</last_name>
    <phone>86-021-38804518</phone>
    <email>lqressh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital, Shanghai Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongmin Liu, Dr.</last_name>
      <phone>+86-021-38804518</phone>
      <email>liu.zhongmin@tongji.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Qiang Li, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Sun, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbilical cord mesenchymal stem cells</keyword>
  <keyword>covid-19 pneumonia</keyword>
  <keyword>refractory hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

